相关实验视频
Updated: May 16, 2025

05:37
An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
2.0K
评估多类结果风险预测模型的临床实用性
Allison N Quintana1, Christopher H Schmid1, Kexin Qu1
1Department of Biostatistics/School of Public Health, Brown University, Providence, RI, USA.
概括
这项研究引入了一种新方法,即sNB曲线下的综合权重面积,用于评估具有多种结果的诊断模型的临床效用. 与世卫组织标准相比,DHAKA和NIRUDAK模型的脱水预测显示出优越的效用.
科学领域:
- 临床流行病学临床流行病学
- 生物统计学 生物统计学
- 健康决策科学 健康决策科学
背景情况:
- 传统的诊断模型评估 (校准,歧视) 不评估实际后果.
- 决策曲线分析 (DCA) 测量了对二元结果的临床效用,但缺乏对多种结果的综合.
- 现有的方法不能为具有多个潜在结果的模型提供单一的实用值.
研究的目的:
- 为了说明多种结局的决策曲线分析 (DCA).
- 为多种结局模型开发一种新的总结实用度量.
- 使用新的测量方法评估脱水严重程度预测模型 (NIRUDAK,DHAKA) 的临床实用性.
主要方法:
- 扩展了DCA概念,以创建sNB曲线下的权重面积 () 对多种结果.
- 提出了按临床重要性加权的平均值,称为sNB曲线下的综合加权面积 (Integrated Weighted Area).
- 应用二进制DCA和集成的逻辑回归模型 (NIRUDAK,DHAKA) 和WHO标准.
主要成果:
- 综合测量被应用来评估NIRUDAK,DHAKA和WHO模型的平均效用.
- 与世卫组织算法相比,DHAKA和NIRUDAK模型都表现出更好的能力来识别受益于治疗的患者.
- 新的措施允许在不同的风险值分布中与"对待所有"或"不对待任何"策略进行比较.
结论:
- 综合结果模型 (Integrated ) 为多种结局模型的临床实用性提供了一个有价值的总结指标.
- 与现有的世卫组织标准相比,DHAKA和NIRUDAK模型在脱水严重程度预测方面提供了更好的临床实用性.
- 这种方法提高了诊断模型在临床决策中的性能的实际评估.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106
Receiver Operating Characteristic Plot
67
A ROC (Receiver Operating Characteristic) plot is a graphical tool used to assess the performance of a binary classification model by illustrating the trade-off between sensitivity (true positive rate) and specificity (false positive rate). By plotting sensitivity against 1 - specificity across various threshold settings, the ROC curve shows how well the model distinguishes between classes, with a curve closer to the top-left corner indicating a more accurate model. The area under the ROC curve...
67
Comparing the Survival Analysis of Two or More Groups
96
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
96
Sensitivity, Specificity, and Predicted Value
149
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
Sensitivity is the...
149
Cancer Survival Analysis
311
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
311
Hazard Ratio
72
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
72

